Although MCL1 inhibition was reported to synergize with HER2-targeting drugs in breast cancer [50], the addition of MCL1i or BCL2i (up to 2 μM) failed to enhance the activity of trastuzumab in HER2-ampfiled GC cells (Fig. S5D and S5E). Here, ERBB2 is linked to breast carcinoma.